← board
NNNN
distress 3/10 · well-funded / low risk$9.45-1%today-82% from 52w high
anbiobiotechnology.com27 employeesFounded 2021Frankfurt am Main, GermanyMedical Instruments & Supplies
Revenue
pre-revenue
Liquidity
$12M
Runway
1.8 yrs
Shares 1y
—
Price & events
-67.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
+3.6%
1W
-42.6%
1M
-66.8%
3M
-67.0%
6M
-76.4%
1Y
—
2Y
—
5Y
+63.8%
All
Overview
- Volume
- 34.10K
- 52 Week Range
- $9.12 – $52.10
- Float Shares
- 39.69M
- Short %
- 0.20%
- % Held by Insiders
- 4.78%
- % Held by Institutions
- 4.90%
- RVOL
- 0.72x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.